Update on HIV pandemic, Retrovirology, vol.9, issue.Suppl 1, p.4 ,
DOI : 10.1186/1742-4690-9-S1-I4
Global HIV/AIDS response -Epidemic update and health sector progress towards universal access, 2011. ,
Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review, PLoS Medicine, vol.15, issue.7, p.1001056, 2011. ,
DOI : 10.1371/journal.pmed.1001056.s002
Integral HIV-STI diagnosis at the first VCT visit as strategy to prevent late ART initiation in the HIV-AIDS program of Mexico City (HIVPMC), Retrovirology, vol.9, issue.Suppl 1, p.73 ,
DOI : 10.1186/1742-4690-9-S1-P73
The Treatment 2.0 Framework for Action: Catalysing the Next Phase of Treatment, Care and Support, 2011. ,
Scaling up HIV treatment -Karnataka, India experience, Retrovirology, vol.9, issue.Suppl 1, p.71 ,
DOI : 10.1186/1742-4690-9-S1-P71
Decentralizing treatment services with link ART centres- experience from Karnataka, South India, Retrovirology, vol.9, issue.Suppl 1, p.82 ,
DOI : 10.1186/1742-4690-9-S1-P82
Access to HIV treatment and care in Armenia, Retrovirology, vol.9, issue.Suppl 1, p.75 ,
DOI : 10.1186/1742-4690-9-S1-P75
Expanding ART for Treatment and Prevention of HIV in South Africa: Estimated Cost and Cost-Effectiveness 2011-2050, PLoS ONE, vol.371, issue.17, p.30216, 2011. ,
DOI : 10.1371/journal.pone.0030216.s001
Newer drugs and earlier treatment, AIDS, vol.26, issue.1, pp.45-56 ,
DOI : 10.1097/QAD.0b013e32834dce6e
Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness, PLoS ONE, vol.5, issue.10, p.13132, 2010. ,
DOI : 10.1371/journal.pone.0013132.s001
HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost???Effectiveness, Clinical Infectious Diseases, vol.48, issue.6, pp.806-815, 2009. ,
DOI : 10.1086/597095
HIV Treatment as Prevention, Science, vol.334, issue.6063, p.1628, 2011. ,
DOI : 10.1126/science.334.6063.1628
"Test and Treat": Is It Enough?, Clinical Infectious Diseases, vol.52, issue.6, pp.801-802, 2011. ,
DOI : 10.1093/cid/ciq254
The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection, Clinical Infectious Diseases, vol.52, issue.6, pp.793-800, 2011. ,
DOI : 10.1093/cid/ciq243
Pre-exposure prophylaxis against HIV: pros and cons, Retrovirology, vol.9, issue.Suppl 1, p.6 ,
DOI : 10.1186/1742-4690-9-S1-I6
Antiretroviral prophylaxis: a defining moment in HIV control, The Lancet, vol.378, issue.9809, pp.23-25, 2011. ,
DOI : 10.1016/S0140-6736(11)61136-7
Animal models of functional HIV cure, Retrovirology, vol.9, issue.Suppl 1, p.9 ,
DOI : 10.1186/1742-4690-9-S1-I9
Molecular control of HIV - 1 postintegration latency: implications for therapeutic strategies, Retrovirology, vol.9, issue.Suppl 1, p.10 ,
DOI : 10.1186/1742-4690-9-S1-I10
Towards a cure for HIV: a long road ahead, Retrovirology, vol.9, issue.Suppl 1, p.12 ,
DOI : 10.1186/1742-4690-9-S1-I12
Search for small molecule activators of latent HIV, Retrovirology, vol.9, issue.Suppl 1, p.2 ,
DOI : 10.1186/1742-4690-9-S1-O2
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation, Immunity, vol.36, issue.3, pp.491-501, 2012. ,
DOI : 10.1016/j.immuni.2012.01.014
Potent suppression of HIV viral replication by a novel inhibitor of Tat, Retrovirology, vol.9, issue.Suppl 1, p.11 ,
DOI : 10.1186/1742-4690-9-S1-O11
New transcription regulatory mechanisms of latent HIV LTR, Retrovirology, vol.9, issue.Suppl 1, p.3 ,
DOI : 10.1186/1742-4690-9-S1-O3
Anti-latency agents to purge HIV reservoirs, Retrovirology, vol.9, issue.Suppl 1, p.16 ,
DOI : 10.1186/1742-4690-9-S1-I16
A roadmap to a cure, Retrovirology, vol.9, issue.Suppl 1, p.11 ,
DOI : 10.1186/1742-4690-9-S1-I11
New antiviral agents for hepatitis C. F1000, Biol Rep, vol.4, issue.5, 2012. ,
New drug interactions in HIV and HCV, Retrovirology, vol.9, issue.Suppl 1, p.8 ,
DOI : 10.1186/1742-4690-9-S1-I8
The history of antiretroviral therapy and of its implementation in resource-limited areas of the world, AIDS, vol.26, issue.10, pp.1231-1241 ,
DOI : 10.1097/QAD.0b013e32835521a3
Managing antiretrovirals in co-infected patients in 2012, Retrovirology, vol.9, issue.Suppl 1, p.1 ,
DOI : 10.1186/1742-4690-9-S1-I1
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics, Expert Opinion on Drug Metabolism & Toxicology, vol.9, issue.5, 2011. ,
DOI : 10.1038/clpt.2009.12
infection: the French experience, Retrovirology, vol.2012, issue.9 1, p.14 ,
Treating since the beginning?, Retrovirology, vol.9, issue.Suppl 1, p.15 ,
DOI : 10.1186/1742-4690-9-S1-I15
Effect of Treatment, during Primary Infection, on Establishment and Clearance of Cellular Reservoirs of HIV-1, The Journal of Infectious Diseases, vol.191, issue.9 ,
DOI : 10.1086/428777
What happens after hepatitis C eradication?, Retrovirology, vol.9, issue.Suppl 1, p.19 ,
DOI : 10.1186/1742-4690-9-S1-I19
Epidemiology of Hepatitis Delta Virus infection in HIV-infected individuals in Taiwan, Retrovirology, vol.9, issue.Suppl 1, p.49 ,
DOI : 10.1186/1742-4690-9-S1-P49
Management and Treatment of Chronic Hepatitis C in HIV Patients, Semin Liver Dis, vol.2012, issue.322, pp.138-146, 2012. ,
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?, Journal of Antimicrobial Chemotherapy, vol.62, issue.1, pp.1-4, 2008. ,
DOI : 10.1093/jac/dkn175
Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals, Retrovirology, vol.2012, issue.9 1, p.7 ,
Hepatitis C as a metabolic disease, Retrovirology, vol.9, issue.Suppl 1, pp.10-1186 ,
DOI : 10.1186/1742-4690-9-S1-I17